The results of a recent study have pointed to various factors that are associated with mortality among antiretroviral therapy-naïve children with human immunodeficiency virus and suspected tuberculosis. ...
The results of a recent phase 3 trial have indicated that a treatment combination could serve as a potential alternative to abacavir plus lamivudine in patients with HIV-1 who achieved virological...
The authors of a recent study aimed to estimate the effects of traditional cardiovascular disease prevention interventions on future cardiovascular health outcomes.
It is well known that initial declines in bone mineral density are common with the initiation of antiretroviral therapy. In a new study, researchers assessed risk factors for decline in women and men with...
The US Food and Drug Administration has approved the smallest integrase strand transfer inhibitor-based triple-therapy single tablet regimen for adults with HIV-1.
Individuals with HIV often have a higher risk of age-related morbidity, despite successful antiretroviral therapy. However, less is known about the risk of accelerated cognitive decline or aging-related...
Two-drug regimens for ART are of interest, in order to minimize drug exposure and toxicity. The efficacy, safety, and tolerability of dolutegravir and rilpivirine suggest that they may be good candidates...
Previous evidence has shown that human immunodeficiency virus and antiretroviral therapy are associated with metabolic disturbances. However, less information currently exists regarding the effect of body...
In a recent study, researchers evaluated the safety and immunogenicity of a new double recombinant vaccine for the prevention of human immunodeficiency virus infection.
